Are Peptides Legal? The U.S. Status in 2026

“Is it legal?” is the most common question people ask about peptides. There is no one answer. “Peptide” is a chemistry word, not a legal one. Whether a specific peptide is legal to sell, own, or use comes down to three things: which exact molecule it is, what it is being sold or used for, and who is selling, making, or holding it. Three different systems of rules cover these substances, and people mix them up all the time. This page is a reference, not legal advice.

Three systems that get conflated

Most of the confusion comes from blending three separate sets of rules. Each one answers a different question.

The FDA (the agency that approves drugs, under a law called the Food, Drug, and Cosmetic Act) decides whether something is an approved drug, an unapproved new drug, or allowed to be mixed up by a pharmacy. This is where most peptide “illegality” actually comes from.
The DEA (the agency that handles controlled substances, under the Controlled Substances Act) decides “scheduling” — that is, which drugs are tightly restricted, like narcotics. Most peptides are not on that restricted list, and people often misread that as “legal.”
WADA (the World Anti-Doping Agency, the global system for sports) sets the rules for athletes. It is a set of agreements athletes sign, not a law. But for competitors, it is the rule that matters.

Here is the single most important thing to get straight: “not a controlled substance” does not mean “legal to sell for people to use.” A peptide can be completely off the DEA’s restricted list and still be an unapproved new drug that is illegal to sell for human use. These are different laws answering different questions.

Approved peptide drugs versus “research use only”

Some peptides are FDA-approved drugs. When a doctor prescribes them and you use them as the label says, they are clearly legal. Insulin has been approved for a hundred years. Newer examples are the GLP-1 and GIP medicines (a class of drugs used for diabetes and weight loss): semaglutide (sold as Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda). How many approved peptide products exist depends on how you define “peptide.” One well-kept database (THPdb2) lists roughly 85 approved peptides and polypeptides, so “around 80-plus” is a fair estimate rather than an official FDA count.

Now compare that to the peptides sold online as “research use only” (RUO) — BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, MOTS-c, epitalon, semax, and others. These are generally unapproved new drugs. Putting “not for human consumption” or “for laboratory research purposes only” on a vial does not make it legal if the seller really expects people to use it. The FDA uses what it calls the “intended use” rule: it looks past the disclaimer at the whole picture — claims on the website, customer testimonials, dosing instructions, and small tells like selling injectable peptides next to bacteriostatic water (sterile water used to mix injections) and syringes. In its standard warning-letter language, the FDA treats products labeled “for laboratory research purposes only” and “not for human consumption” as drugs meant for people whenever the marketing shows that is the real intent.

The FDA has acted on this again and again. Warning letters to USA Peptide (February 2025), Summit Research Peptides (December 2024), and Gram Peptides (March 2026) all point to the RUO label paired with marketing — weight-loss claims, dosing, accessories — that showed the products were really meant for human use. We dig into the disclaimer in Research Use Only, Explained and the bigger supply picture in The Gray Market.

Selling versus possessing

The federal rules come down hardest on selling. Selling, distributing, or marketing an unapproved peptide for people to use breaks the FD&C Act, either as an unapproved new drug or a misbranded one. This is where FDA enforcement is focused: warning letters, seizures, court orders, and — in the worst cases — criminal charges.

Simply owning a non-controlled peptide for personal use is generally not, by itself, a federal crime under the FD&C Act. That is because the Act goes after the business chain — making, distributing, and shipping products across state lines. But that is a narrow technical point, not a green light. It does not mean the substance is safe, that using it is approved, that you can legally import it (the FDA can refuse or hold shipments at the border), or that your state allows it.

One peptide has its own much tougher set of rules. Under a law called 21 U.S.C. § 333(e), knowingly distributing human growth hormone — or holding it with the intent to distribute it — for any use in people other than treating a disease or recognized medical condition that HHS has authorized and a doctor has ordered, is a federal crime. The penalty is up to 5 years in prison (up to 10 if it is given to someone under 18). Human growth hormone (hGH) is not on the DEA’s restricted list, yet this separate law makes off-label distribution a serious crime on its own.

Pharmacy compounding: the heart of the 2026 story

“Compounding” means a pharmacy custom-mixes a medicine. Compounding pharmacies (which work under a rule called section 503A and fill prescriptions for one specific patient) and outsourcing facilities (under section 503B, which make larger batches) can compound from a raw drug ingredient (a “bulk drug substance”) only if one of three things is true: it has an official quality standard (a “USP monograph”), it is an ingredient in an FDA-approved drug, or it appears on a list the FDA has built called the “503A bulks list.” For ingredients the FDA has not yet ruled on, its Interim Policy sorts them into groups: Category 1 ingredients get “enforcement discretion,” meaning the FDA tolerates compounding them while it works out formal rules, while Category 2 ingredients carry “significant safety risks,” so the FDA will not tolerate them — which effectively bans compounding them.

In September 2023, the FDA put BPC-157 and a group of popular peptides into Category 2, pointing to the risk of an immune reaction (immunogenicity), impurities tied to how peptides are made, and the limited human safety data.

Then things shifted in a big way. On April 15–16, 2026, through an update to its 503A bulk-substances list and a notice in the Federal Register (the government’s official record of rules), the FDA said it was removing 12 peptides from Category 2 and calling together its Pharmacy Compounding Advisory Committee (PCAC). This is the most misreported news of the year, so let’s be very clear: taking these peptides out of Category 2 does not put them on the bulks list, does not make them Category 1, and does not make compounding them allowed. They now sit in a regulatory gray zone, waiting on the committee’s review and — if the committee recommends it — a full public rulemaking process. That process can take more than a year.

The committee’s first meeting is set for July 23–24, 2026 at FDA White Oak. It will review seven peptides: BPC-157, KPV, TB-500, and MOTS-c on July 23, and emideltide (DSIP), semax, and epitalon on July 24. A second meeting, expected before the end of February 2027, will cover the other five: GHK-Cu, melanotan II, cathelicidin (LL-37), dihexa acetate, and PEG-MGF. As news reporting (not as settled legal fact), this reconsideration follows a public push by HHS Secretary Robert F. Kennedy Jr. for wider peptide access, which he described in early 2026. Supporters of the change argue the original Category 2 decision lumped in compounds of real medical interest based on thin evidence, and that a fresh look is overdue. Critics, such as the group Public Citizen, warn it lowers the safety bar. The disagreement is the useful part: these labels are contested policy choices that shift with whoever is making them, not settled science. A compound’s regulatory tier in 2026 tells you more about where the rulemaking stands than about what the molecule actually does.

The practical takeaway: as of June 2026, BPC-157 and the other peptides under review are not legal to compound. Their status is “under active FDA reconsideration,” and both the outcome and the timing are uncertain.

The GLP-1 compounding situation

Compounding a drug that is already FDA-approved is generally not allowed — unless that drug is on the FDA’s shortage list. The boom in compounded GLP-1 medicines rode exactly that exception, and the exception has now closed. The FDA confirmed that the tirzepatide shortage was resolved on December 19, 2024, and set deadlines to stop compounding: February 18, 2025 (for 503A pharmacies) and March 19, 2025 (for 503B facilities). Semaglutide came off the shortage list on February 21, 2025, with deadlines of April 22 and May 22, 2025.

In 2026 the FDA went further. On April 30, 2026 (with the Federal Register notice published May 1), it proposed to leave semaglutide, tirzepatide, and liraglutide off the 503B bulks list, finding no “clinical need” for them there. That would permanently block large-scale compounding of these drugs from raw ingredient by outsourcing facilities. The public comment period closes June 30, 2026.

One subtle point: small-batch, patient-specific 503A compounding of a drug you can already buy can still be legal when there is a documented medical reason for one person — for example, a real allergy to an inactive ingredient. What is no longer protected is the routine mass production of “compounded semaglutide.” And “research use only” semaglutide or tirzepatide powder sold online is a completely separate problem: that is an unapproved drug, not compounding.

DEA scheduling

Most peptides are not controlled substances. BPC-157, TB-500, GHK-Cu, the GLP-1 medicines, and growth-hormone secretagogues (compounds that prompt the body to release growth hormone) like ipamorelin are not on the DEA’s restricted list (the CSA schedules). Here is the trap worth repeating: being off that restricted list is not permission to sell a peptide for people to use, because FDA unapproved-drug law still applies. The main exception is human growth hormone — controlled not by DEA scheduling but by the separate criminal law described above. Before you rely on any specific compound’s status, check the official DEA schedules yourself rather than trusting a seller’s summary.

Athletes: WADA bans most peptides outright

For athletes who compete under WADA’s rules, a peptide’s status is set by the 2026 Prohibited List (in force as of January 1, 2026), completely separate from FDA or DEA status. Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — is banned at all times, both in and out of competition, under “strict liability” (meaning the athlete is responsible if it’s in their body, even by accident). This section covers EPO and similar agents, growth hormone along with its fragments and releasing factors, growth-hormone secretagogues (named examples include ibutamoren/MK-677, ipamorelin, the GHRPs, hexarelin, and others), and growth factors such as IGF-1, MGF, VEGF, PDGF, FGF, and TB-500.

BPC-157 is not named outright on the 2026 list, but it is still caught — by the catch-all wording for substances with a similar structure or biological effect under S2, and by the non-approved-substance catch-all (S0). Either way, it is banned at all times. By contrast, the GLP-1 medicines semaglutide and tirzepatide are not banned under WADA 2026. They sit on the Monitoring Program instead (semaglutide added in 2024, tirzepatide in 2026), which surprises a lot of people. For a fuller look, see Peptides and Anti-Doping.

Bottom line

There is no one-size-fits-all answer to “are peptides legal.” Approved peptide drugs are legal when prescribed and used as labeled. The “research use only” peptides sold online are generally unapproved new drugs, and the RUO label does not erase the fact that they are really meant for human use. Selling for human use is the main federal violation. Owning a non-controlled peptide for yourself is a gray area, but it is not FDA-approved, and hGH has its own criminal law. Compounding turns on the 503A/503B rules — and even though the FDA removed 12 peptides from Category 2 in April 2026, none of them can be legally compounded yet, with committee reviews stretching into 2027. Most peptides are not on the DEA’s restricted list, but that is not permission to sell them for people. And for athletes, the S2 peptides are banned at all times. If you are weighing any of this, check the current status of the specific molecule against original government sources, because this area changes month to month. And when you read claims about safety or quality, our guides on how to read a certificate of analysis and independent testing explain why a legal-status label tells you nothing about what is actually in a vial.

Sources

New profiles and evidence updates only. No spam, and we never sell or share your email.